Data / Research funding / Huntington's Disease
Huntington's Disease: 157 NIH awards ($205.5M) to 71 organizations
157 NIH awards ($205.5M) in the NIH spending category Huntington's Disease, to 71 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
157 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Admin. Supp.: Correction of Neurological Disease via Allele Specific Excision of Pathogenic Repeats | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $13,703,967 | May 15, 2023 | April 30, 2028 | DOUDNA, JENNIFER A | reporter.nih.gov |
| Growth and development of Striatal-Cerebellum circuitry in subjects at risk for Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $10,413,314 | March 1, 2009 | August 31, 2026 | NOPOULOS, PEGGY C | reporter.nih.gov |
| Molecular Mechanisms of Pathogenesis in Huntington’s disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $6,238,150 | May 1, 2020 | April 30, 2028 | THOMPSON, LESLIE MICHELS | reporter.nih.gov |
| La Spada Outstanding Investigator Award | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $6,002,158 | May 15, 2021 | April 30, 2029 | LA SPADA, ALBERT R | reporter.nih.gov |
| Advancing RNA Therapeutics for Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $5,226,511 | February 1, 2020 | January 31, 2026 | ARONIN, NEIL | reporter.nih.gov |
| Contribution of RAN proteins to HD, SCA3 other CAG.CTG expansion diseases | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,408,902 | July 15, 2021 | June 30, 2027 | RANUM, LAURA P.W | reporter.nih.gov |
| Correlating molecular behavioral phenotypes in a marmoset model of Huntingtons disease | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,130,636 | August 1, 2021 | May 31, 2026 | BRIVANLOU, ALI H | reporter.nih.gov |
| Huntington's Disease: Learning from Extremes | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $3,033,360 | September 15, 2018 | June 30, 2025 | ROSAS, HERMINIA DIANA | reporter.nih.gov |
| The Pathogenic Role of Interneurons in Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,012,470 | December 1, 2020 | November 30, 2026 | MOLERO, ALDRIN ENRIQUE | reporter.nih.gov |
| Genetic Mechanisms Controlling Resilience to Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,889,497 | December 1, 2021 | November 30, 2027 | KACZOROWSKI, CATHERINE COOK | reporter.nih.gov |
| Molecular Mechanism of Huntingtin Misfolding and its Inhibition by Designed and Cellular Proteins | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,856,348 | September 17, 2021 | August 31, 2026 | LANGEN, RALF | reporter.nih.gov |
| Interneurons as Early Drivers of Huntington´s Disease Progression | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,763,048 | August 1, 2022 | July 31, 2027 | MEHLER, MARK F | reporter.nih.gov |
| Disease-Modifying Genes in Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,741,066 | April 1, 2015 | March 31, 2026 | GUSELLA, JAMES F | reporter.nih.gov |
| Expanding the Chemical Diversity of Therapeutic Oligonucleotides | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,703,592 | September 25, 2017 | March 31, 2028 | KHVOROVA, ANASTASIA | reporter.nih.gov |
| Understanding the Contribution of Altered Cerebrovascular Function to the Pathology and Clinical Symptoms of Huntington Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,681,561 | December 15, 2020 | May 31, 2027 | ROSAS, HERMINIA DIANA | reporter.nih.gov |
| Huntington's Disease Repeat Instability and Pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,671,962 | September 1, 2005 | March 31, 2027 | WHEELER, VANESSA C | reporter.nih.gov |
| Therapeutic Potential of Base Editing Strategies to Convert CAG to CAA in Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,630,329 | December 15, 2020 | November 30, 2026 | LEE, JONG-MIN | reporter.nih.gov |
| Chemical Fingerprinting | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,611,442 | July 1, 2007 | January 31, 2026 | POLYZOS, ARIS A | reporter.nih.gov |
| Genetically Encoded Probes of Huntingtin Misfolding | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,585,754 | August 1, 2022 | July 31, 2027 | LANGEN, RALF | reporter.nih.gov |
| Advanced MRI biomarkers in HD mouse models translatable to humans: nature history and response to therapeutics | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,585,010 | August 1, 2022 | July 31, 2027 | DUAN, WENZHEN | reporter.nih.gov |
| Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,581,449 | March 5, 2022 | February 28, 2027 | COMPAS, BRUCE E | reporter.nih.gov |
| COX-2-Selective PET Imaging as an Onset Marker of Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,509,953 | December 1, 2019 | November 30, 2025 | HOOKER, JACOB M. | reporter.nih.gov |
| Understanding the Cellular Basis of Movement Disorders | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,269,547 | August 17, 2013 | November 30, 2029 | OPAL, PUNEET | reporter.nih.gov |
| Nonneuronal Mechanisms of Polyglutamine Neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,168,545 | September 30, 2021 | June 30, 2026 | MCLOUGHLIN, HAYLEY S | reporter.nih.gov |
| Molecular Mechanisms Underlying Cell Type-Specific Vulnerability in Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,155,114 | May 1, 2022 | April 30, 2030 | HEIMAN, MYRIAM | reporter.nih.gov |
| Regulation of HTT-mediated DNA damage repair and chromatin remodeling Complexes | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,008,557 | September 20, 2023 | August 31, 2028 | SARKAR, PARTHA S | reporter.nih.gov |
| Mitofusin Agonists to Treat Neurodegenerative Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $1,954,883 | May 15, 2022 | April 30, 2025 | HAUGER, DEBORAH ANN | reporter.nih.gov |
| Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24 Clinical Trial Not Allowed) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,950,438 | July 15, 2018 | June 30, 2028 | MARDER, KAREN S | reporter.nih.gov |
| Molecular mechanisms of triplet repeat instability in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,938,300 | July 1, 2021 | June 30, 2027 | PLUCIENNIK, ANNA | reporter.nih.gov |
| Rare Variant Whole Genome Analysis and iPSC Validation of Putative Genetic Modifiers of Huntington Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,931,388 | April 1, 2017 | March 31, 2024 | FINKBEINER, STEVEN M | reporter.nih.gov |
| Novel mouse genetic models to study modifiers of Huntington’s disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,928,952 | July 1, 2019 | June 30, 2025 | YANG, XIANGDONG WILLIAM | reporter.nih.gov |
| Dissecting the role of DNA Ligase 1 in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,927,817 | July 25, 2023 | June 30, 2028 | WHEELER, VANESSA C | reporter.nih.gov |
| Exploring the contribution of astrocytes to Huntington disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,911,527 | August 1, 2015 | June 30, 2026 | GRAY, MICHELLE | reporter.nih.gov |
| Characterizing the Conformations and Neurotoxic Species of Huntingtin | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,909,531 | July 1, 2023 | June 30, 2027 | KHOSHNAN, ALI | reporter.nih.gov |
| Molecular mechanisms of synaptic dysfunction and cognitive decline in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,909,412 | December 15, 2019 | March 31, 2030 | GOMEZ-PASTOR, ROCIO | reporter.nih.gov |
| A Vascularized Micro-Organ platform for the study of Brain-BBB-Blood interaction | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $1,904,995 | September 3, 2020 | August 31, 2025 | HUGHES, CHRISTOPHER C. W. | reporter.nih.gov |
| Preparing for preventive clinical trials in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,876,227 | March 15, 2018 | January 31, 2026 | PAULSEN, JANE S | reporter.nih.gov |
| Determining Selective Autophagy Kinase in Modulating Neurotoxicity in Huntington's Disease Model | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,857,741 | July 15, 2020 | June 30, 2025 | YUE, ZHENYU | reporter.nih.gov |
| Validation of Novel Pathogenic Post-Translational Modifications of Huntingtin, and of Modifying Enzymes as Therapeutic Targets for Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,815,246 | April 1, 2014 | January 31, 2025 | ROSS, CHRISTOPHER A | reporter.nih.gov |
| Improved Delivery of Gene Therapies to the Central Nervous System by Focused Ultrasound-Mediated Disruption of the Blood-Brain Barrier | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,791,568 | May 1, 2022 | March 31, 2027 | TODD, NICHOLAS E. | reporter.nih.gov |
| Resilience pathways modeling human longevity-promoting ApoE variants in induced pluripotent stem cells | NIH | National Institute on Aging | 2021 to 2022 | $1,759,184 | September 30, 2018 | May 31, 2025 | ELLERBY, LISA M | reporter.nih.gov |
| Developing a Robust and Efficient Strategy for Censored Covariates to Improve Clinical Trial Design for Neurodegenerative Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,730,255 | June 1, 2023 | April 30, 2028 | GARCIA, TANYA PAMELA | reporter.nih.gov |
| Decoding cerebrospinal fluid huntingtin biomarkers | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,711,210 | April 15, 2020 | March 31, 2026 | SOUTHWELL, AMBER L | reporter.nih.gov |
| Long-term effects of wildtype huntingtin lowering in the primate corticostriatal tract and thalamus | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,697,365 | April 1, 2020 | March 31, 2026 | GRONDIN, RICHARD C. | reporter.nih.gov |
| Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,647,634 | February 1, 2022 | January 31, 2027 | ZEITLIN, SCOTT | reporter.nih.gov |
| Molecular Mechanisms of Motility Deduced from in Vitro Reconstituted Microtubule- and Actin-Based Motor Complexes | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,627,562 | April 1, 2020 | March 31, 2025 | TRYBUS, KATHLEEN M | reporter.nih.gov |
| Replication through DNA Structures and Consequences for Genome Stability | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,623,623 | January 1, 2022 | December 31, 2026 | FREUDENREICH, CATHERINE H | reporter.nih.gov |
| Epigenetic Pathology and Therapy in Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,621,733 | April 1, 2015 | May 31, 2025 | FRAENKEL, ERNEST | reporter.nih.gov |
| Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $1,618,550 | September 21, 2022 | August 31, 2024 | DIDSBURY, JOHN | reporter.nih.gov |
| The Discovery of Molecules and Mechanisms of the Rhomboid Superfamily | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,617,635 | August 15, 2019 | December 31, 2029 | NEAL, SONYA ELINA | reporter.nih.gov |
| Regulation of lysosome positioning and function by the unfolded protein response | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,613,210 | September 1, 2016 | August 31, 2026 | HOLLIEN, JULIE | reporter.nih.gov |
| Somatic Repeat Expansions as a Therapeutic Target for Trinucleotide Repeat Disorders | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,596,958 | April 15, 2022 | March 31, 2027 | MOURO PINTO, RICARDO | reporter.nih.gov |
| Identifying Factors Regulating Medium Spiny Neuron Differentiation or Maintenance as Therapeutic Targets for Huntington's Disease using Induced Pluripotent Stem Cells | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,594,872 | September 30, 2016 | April 30, 2029 | ELLERBY, LISA M | reporter.nih.gov |
| Molecular Studies of Spinocerebellar Ataxia Type 1 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,592,963 | September 1, 1989 | June 30, 2027 | ZOGHBI, HUDA Y | reporter.nih.gov |
| An Alternative Isoform of RRM2B as a Genetic Modifier in Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,567,356 | July 1, 2020 | April 30, 2026 | SEONG, IHN SIK | reporter.nih.gov |
| MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,501,141 | July 1, 2017 | March 31, 2027 | FINK, KYLE | reporter.nih.gov |
| Nuclear sphingosine kinase 2 in Huntington disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,501,103 | September 15, 2020 | May 31, 2026 | TSVETKOV, ANDREY | reporter.nih.gov |
| Emerging role of glymphatic clearance in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,482,773 | April 1, 2023 | March 31, 2028 | DUAN, WENZHEN | reporter.nih.gov |
| A novel force spectroscopy to study the ribosome power strokes and frameshifting | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,479,596 | September 1, 2015 | August 31, 2025 | WANG, YUHONG | reporter.nih.gov |
| Rhes-SUMO Pathway in Huntington disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $1,469,201 | September 21, 2022 | August 31, 2027 | SUBRAMANIAM, SRINI | reporter.nih.gov |
| APE1 and Somatic Expansion in Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,406,505 | February 1, 2022 | January 31, 2027 | AYALA-PENA, SYLVETTE | reporter.nih.gov |
| Engineering Smart Antibody-like Protein Scaffolds with precision switches | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,349,563 | September 22, 2022 | August 31, 2026 | ZHOU, YUBIN | reporter.nih.gov |
| Novel chaperones and neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,296,556 | July 1, 2019 | April 30, 2025 | SCAGLIONE, KENNETH MATTHEW | reporter.nih.gov |
| The Roles of Huntingtin Associated Protein 40 in Huntingtin Functions and Huntington's Disease Pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,289,985 | April 1, 2019 | March 31, 2025 | ZHANG, SHENG | reporter.nih.gov |
| Identification of novel pathogenic tandem repeat expansions using long read sequencing | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,246,369 | September 30, 2018 | July 31, 2023 | SHARP, ANDREW JAMES | reporter.nih.gov |
| Modulating selective autophagy to modify Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,246,116 | April 1, 2012 | March 31, 2025 | YAMAMOTO, AI | reporter.nih.gov |
| Role of DNA methyltransferases in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $1,208,527 | May 1, 2019 | April 30, 2025 | YANO, HIROKO | reporter.nih.gov |
| Genetic Mechanisms Controlling Resilience to Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $1,186,634 | December 1, 2021 | February 28, 2023 | KACZOROWSKI, CATHERINE COOK | reporter.nih.gov |
| Statistical disease modeling and clinimetrics to prepare for preventive trials in huntington disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,086,014 | July 1, 2017 | March 31, 2025 | PAULSEN, JANE S | reporter.nih.gov |
| Crosstalk between DNA repair pathways in repeat instability | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,075,966 | February 1, 2023 | December 31, 2026 | PLUCIENNIK, ANNA | reporter.nih.gov |
| Huntingtin links inflammasome pathway in Huntington's disease Pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,069,321 | February 1, 2024 | January 31, 2029 | JIANG, MALI | reporter.nih.gov |
| A Wearable Sensor Platform for Remote Monitoring of Motor Impairment in Huntingtons Disease and Prodromal Huntingtons Disease | NIH | National Center for Advancing Translational Sciences | 2025 | $1,064,194 | September 1, 2025 | August 31, 2027 | VAZIRI, ASHKAN | reporter.nih.gov |
| Characterizing the Conformations and Neurotoxic Species of Huntingtin | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $1,027,183 | July 15, 2021 | June 30, 2023 | KHOSHNAN, ALI | reporter.nih.gov |
| Selective Editing of the Mutant Huntingtin Gene | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $936,493 | April 1, 2018 | March 31, 2024 | ARONIN, NEIL | reporter.nih.gov |
| Investigating Autonomic Dysfunction as an Early Pathologic Feature of Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $894,852 | April 1, 2021 | May 8, 2025 | SCHULTZ, JORDAN | reporter.nih.gov |
| Genetic foundation for complete mutant allele-specific CRISPR in neurodegenerative diseases | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $887,184 | September 15, 2018 | June 30, 2025 | LEE, JONG-MIN | reporter.nih.gov |
| The role of mito-nuclear communication in the adaptation to mitochondrial dysfunction and stress resistance | NIH | National Institute of General Medical Sciences | 2023 to 2024 | $826,279 | August 1, 2023 | January 1, 2025 | KAYA, ALAATTIN | reporter.nih.gov |
| Use of CRISPR/Cas9 to Treat Huntington Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $778,327 | May 1, 2021 | April 30, 2024 | YAO, BING | reporter.nih.gov |
| Development of ferroptosis inhibitors for Huntington Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $777,642 | August 15, 2021 | July 31, 2023 | STOCKWELL, BRENT R. | reporter.nih.gov |
| From hybrid to Tribrid: A refurbished Orbitrap Eclipse Tribrid Mass Spectrometer | NIH | Office of the Director, National Institutes of Health | 2025 | $738,091 | July 15, 2025 | July 14, 2026 | GERSHON, PAUL D | reporter.nih.gov |
| Unbiased longitudinal neuromorphometry for clinical decision support | NIH | National Institute on Aging | 2021 | $734,079 | July 1, 2019 | May 31, 2023 | SCHMANSKY, NICHOLAS JOHN | reporter.nih.gov |
| Inhibitory Control and Externalizing Behaviors in Youth at Risk for Huntington Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $707,159 | August 15, 2022 | July 31, 2027 | MCDONELL, KATHERINE | reporter.nih.gov |
| Proteomics of the Proteasome Interacting Networks | NIH | National Institute of General Medical Sciences | 2021 to 2022 | $706,500 | August 1, 2005 | June 30, 2023 | HUANG, LAN | reporter.nih.gov |
| Mechanistic insights into neurodegeneration in Huntington's disease using patient-derived neurons through direct conversion of fibroblasts | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $667,188 | July 1, 2018 | June 30, 2024 | YOO, ANDREW | reporter.nih.gov |
| A Vascularized Micro-Organ platform for the study of Brain-BBB-Blood interaction | NIH | National Heart, Lung, and Blood Institute | 2021 | $642,429 | September 3, 2020 | August 31, 2022 | HUGHES, CHRISTOPHER C. W. | reporter.nih.gov |
| IMPROVED MONITORING OF PREMANIFEST AND EARLY HUNTINGTONS USING 7T MULTIMODAL MRI | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $626,757 | July 1, 2017 | June 30, 2023 | LUPO, JANINE MARIE | reporter.nih.gov |
| Cerebrospinal fluid dynamics in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $621,073 | January 1, 2025 | December 31, 2029 | CLAASSEN, DANIEL OLIVER | reporter.nih.gov |
| Characterization of small molecules that lower mutant huntingtin protein as potential therapeutics for Huntington’s disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $609,996 | September 15, 2023 | July 31, 2025 | HOFFMAN, BETH J | reporter.nih.gov |
| Engineering Saffron Plant Cell Culture to Produce Neuroprotective Bioactives | NIH | National Center for Complementary & Integrative Health | 2024 to 2025 | $604,784 | April 5, 2024 | March 31, 2026 | GLENN, WESLEE SINCLAIR | reporter.nih.gov |
| Tracing Spread of Pathology Within The HD Brain via Automated Neuroimaging | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $599,142 | June 15, 2018 | April 30, 2023 | MILLER, MICHAEL I | reporter.nih.gov |
| The role of mito-nuclear communication in the adaptation to mitochondrial dysfunction and stress resistance | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $571,920 | August 1, 2023 | May 31, 2028 | KAYA, ALAATTIN | reporter.nih.gov |
| CRMP2, mitochondria, and Huntington’s disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $561,046 | April 1, 2017 | February 29, 2024 | BRUSTOVETSKY, NICKOLAY | reporter.nih.gov |
| Convergence of tauopathy and Huntington's disease through selective autophagy | NIH | National Institute on Aging | 2021 | $558,425 | September 30, 2017 | May 31, 2022 | ZHENG, HUI | reporter.nih.gov |
| Modulation of neuronal atrophy in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $551,250 | September 1, 2018 | August 31, 2025 | LEE, JUNGHEE | reporter.nih.gov |
| Predicting neurodegeneration in living patients by IR imaging of skin fibroblasts | NIH | National Institute on Aging | 2022 | $541,295 | August 1, 2022 | July 31, 2025 | POLYZOS, ARIS A | reporter.nih.gov |
| DNA double strand break repair deficiency and neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $536,032 | July 1, 2012 | February 28, 2026 | HAZRA, TAPAS K | reporter.nih.gov |
| Small molecule mitochondria-targeted therapeutics for Huntingtons Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $535,142 | June 15, 2018 | April 30, 2022 | TRUSHINA, EUGENIA | reporter.nih.gov |
| Validating cGAS-STING pathway as drug target in Huntington disease mouse model | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $531,300 | September 20, 2022 | November 30, 2024 | SUBRAMANIAM, SRINI | reporter.nih.gov |
| Advanced MRI biomarkers in HD mouse models translatable to humans: nature history and response to therapeutics | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $522,391 | August 1, 2021 | July 30, 2022 | DUAN, WENZHEN | reporter.nih.gov |
| Pre-Clinical Evaluation of a Rationally Designed Nanotherapeutic for Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $518,505 | September 1, 2021 | June 30, 2025 | MOLOKANOVA, ELENA | reporter.nih.gov |
| Uncovering the molecular target(s) of ORI-113, a potential brain-penetrant small molecule therapeutic for Huntington's disease. | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $499,988 | August 13, 2025 | February 28, 2027 | HOFFMAN, BETH J | reporter.nih.gov |
| In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $490,501 | September 15, 2025 | February 28, 2027 | SCHILB, ANDREW LORING | reporter.nih.gov |
| Mechanisms of Translational Dysregulation in Huntington disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $483,000 | July 1, 2024 | May 31, 2025 | SUBRAMANIAM, SRINI | reporter.nih.gov |
| Endogenous regulation of huntingtin expression as a therapeutic target for Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $470,932 | September 15, 2017 | June 30, 2023 | MARGOLIS, RUSSELL L | reporter.nih.gov |
| Brain-targeted delivery of therapeutic molecules by exosomes derived from engineered human iPS cells: a potential therapeutic approach for Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $465,261 | January 15, 2023 | December 31, 2025 | LI, PAN | reporter.nih.gov |
| Identifying New Astrocytic Kir4.1 Channel Modulators for Treating Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $464,750 | April 1, 2023 | March 31, 2025 | SLESINGER, PAUL A | reporter.nih.gov |
| Developing novel nanobody-based biosensors and therapeutics for Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $456,313 | April 15, 2024 | March 31, 2027 | KHOSHNAN, ALI | reporter.nih.gov |
| Understanding the Relationship Between Protein Homeostasis and Sleep Dysfunction in Mouse Models of Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $452,375 | September 27, 2022 | August 31, 2024 | PENG, YUEQING | reporter.nih.gov |
| Comparison of HD and HDL2 mouse models to reveal common mechanisms of pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $450,313 | September 15, 2021 | March 14, 2024 | MARGOLIS, RUSSELL L | reporter.nih.gov |
| In vivo efficacy of a kinase inhibitor, roscovitine, in HD mouse model | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $450,313 | September 19, 2022 | August 31, 2025 | JIN, JING | reporter.nih.gov |
| Developing HTS assays for identifying NLK activators to target Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $450,313 | September 14, 2023 | August 31, 2025 | DUAN, WENZHEN | reporter.nih.gov |
| Phosphoinositide signaling: novel potential targets for Huntington disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $449,225 | August 15, 2017 | May 31, 2023 | WEISMAN, LOIS S | reporter.nih.gov |
| N-terminal huntingtin and Huntington disease neuropathology | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $448,409 | March 1, 2017 | February 28, 2023 | ESCAYG, ANDREW P | reporter.nih.gov |
| Environmental drivers of trinucleotide repeat instability and Huntington's disease onset | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $445,500 | April 21, 2021 | March 31, 2024 | PEARSON, BRANDON L | reporter.nih.gov |
| Molecular Origins of Neurodegeneration through Force Detangling of Toxic RNA | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $442,251 | March 15, 2023 | February 28, 2025 | WOODSON, SARAH A. | reporter.nih.gov |
| Deficient Neuronal Glucose Transport Underlies Cortical Hyperexcitability in Mouse Models of Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $429,000 | March 1, 2022 | February 28, 2025 | DEVASKAR, SHERIN U | reporter.nih.gov |
| Somatic instability of CAG repeats in spinal and bulbar muscular atrophy | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $429,000 | May 15, 2025 | April 30, 2027 | MERRY, DIANE E | reporter.nih.gov |
| Development of MESH1 inhibitors to treat ferroptosis-associated neurodegeneration | NIH | National Institute on Aging | 2022 | $427,817 | September 1, 2022 | August 31, 2024 | HONG, JIYONG | reporter.nih.gov |
| Therapeutic targeting of DNA methyltransferases in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $427,625 | March 1, 2024 | February 28, 2027 | YANO, HIROKO | reporter.nih.gov |
| White matter-associated striatal astrocytes and their role in apathy in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $426,250 | March 15, 2024 | February 28, 2026 | GOMEZ-PASTOR, ROCIO | reporter.nih.gov |
| Chemical Probes as Allosteric Modulators of CK2 Alpha Prime Targeting Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $416,865 | February 15, 2021 | January 31, 2023 | GOMEZ-PASTOR, ROCIO | reporter.nih.gov |
| Immortalized Striatal Precursor Neurons as a Screenable Model of HD | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $409,375 | September 1, 2018 | December 31, 2023 | ROSS, CHRISTOPHER A | reporter.nih.gov |
| Targeted Circuit Manipulation for Ameliorating Huntington's Disease Pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $402,805 | May 1, 2023 | April 30, 2026 | HOCHGESCHWENDER, UTE H | reporter.nih.gov |
| Development of a novel, RNA-interference-based therapeutic to treat prostate cancer | NIH | National Cancer Institute | 2024 | $400,000 | September 19, 2024 | August 31, 2025 | SCHICKEL, ROBERT | reporter.nih.gov |
| Neuronal function of huntingtin-associated protein | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $396,395 | January 1, 1998 | February 28, 2023 | ESCAYG, ANDREW P | reporter.nih.gov |
| Unraveling the role of the molecular co-chaperone DNAJC7 in protein homeostasis and neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $391,140 | August 1, 2024 | June 30, 2029 | RAMANI, BISWARATHAN | reporter.nih.gov |
| In vivo targeting of unfolded protein to a phase-separated Huntingtin inclusion | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $371,521 | April 9, 2020 | March 31, 2025 | EMTAGE, LESLEY RACHEL | reporter.nih.gov |
| Determinants of cell type-specific vulnerability in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $365,000 | July 1, 2021 | March 31, 2022 | HEIMAN, MYRIAM | reporter.nih.gov |
| Role of serotonergic-activation of heat shock transcription factor in the regulation of age-related protein misfolding and toxicity in mammalian systems | NIH | National Institute on Aging | 2021 to 2022 | $363,731 | September 5, 2021 | June 30, 2023 | PRAHLAD, VEENA | reporter.nih.gov |
| High-throughput small molecule screen to reduce endogenous level of Msh3 for disease-modifying HD therapy | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $345,114 | January 22, 2025 | December 31, 2026 | YANG, XIANGDONG WILLIAM | reporter.nih.gov |
| Mitochondrial Fragmentation and Neurodegeneration in Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $318,653 | September 25, 2017 | July 31, 2023 | REDDY, P. HEMACHANDRA | reporter.nih.gov |
| Shared Resource in Cellular Imaging | NIH | National Institute of Mental Health | 2023 | $283,310 | September 1, 2023 | August 31, 2024 | VASUDEVAN, ANJU | reporter.nih.gov |
| Pharmacokinetic Assessment of Peptide-Based Therapy HV-3 for the Treatment of Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $240,938 | December 15, 2020 | May 31, 2023 | SCHILB, ANDREW LORING | reporter.nih.gov |
| Understanding small molecule modulation of splicing for Huntington's disease therapy | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $195,000 | April 1, 2025 | March 31, 2027 | ZHAO, RUI | reporter.nih.gov |
| Development of a Conditional Inducible Huntington’s Disease Murine Model to Study Complex Pathogenic Mechanisms | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $168,000 | September 1, 2021 | February 28, 2025 | MEHLER, MARK F | reporter.nih.gov |
| Nanoscopic Membrane Modulations Induced by Nanoscale Oligomers | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $141,650 | September 8, 2023 | August 31, 2025 | PAN, JIANJUN | reporter.nih.gov |
| Generation of new neurons in the aging adult brain: identifying mechanisms of adult neurogenesis by exploiting single cell spatial transcriptomics. | NIH | National Institute on Aging | 2025 | $126,956 | April 1, 2025 | February 28, 2026 | MAIMON, ROY | reporter.nih.gov |
| Time restricted feeding rescues circadian and motor dysfunction in a mouse model of Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $124,446 | December 1, 2019 | November 30, 2021 | COLWELL, CHRISTOPHER SCOTT | reporter.nih.gov |
| Elucidating the impact of FIC-1/FICD-mediated AMPylation on polyglutamine aggregation dynamics and toxicity | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $123,094 | July 1, 2022 | June 30, 2025 | VAN PELT, KATE MATTHYS | reporter.nih.gov |
| RNA helicases to combat RNA phase transitions in repeat expansion disorders | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $116,947 | December 1, 2023 | June 30, 2025 | MILLER, LINAMARIE | reporter.nih.gov |
| Dissecting Key Interactions of the HTT Transcription Coupled Repair Complex | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $99,401 | September 1, 2024 | December 1, 2025 | PENDLEBURY, DEVON | reporter.nih.gov |
| Effect of small peptide binders on huntingtin fibrillization and toxicity | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $94,396 | June 20, 2022 | June 19, 2024 | FULTZ, ELISSA | reporter.nih.gov |
| Effect of Mutant HTT on the Development and Maturation of Astrocytes | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $93,064 | September 1, 2024 | August 31, 2026 | BURNS, MARA | reporter.nih.gov |
| Mechanisms of mutanthuntingtin aggregate engulfment and spreading by phagocytic glia | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $93,024 | August 19, 2022 | August 31, 2023 | PEARCE, MARGARET PANNING | reporter.nih.gov |
| The Impact of Nucleotide Modification Patterns on Therapeutic Small Interfering RNA Activity in the Central Nervous System | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $90,626 | December 19, 2021 | September 18, 2024 | HILDEBRAND, SAMUEL | reporter.nih.gov |
| Stress, Inflammation, and Neurocognitive Functioning in Adults with Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $86,188 | December 1, 2023 | October 5, 2025 | CIRIEGIO, ABAGAIL ELIZABETH | reporter.nih.gov |
| MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $78,500 | March 15, 2021 | July 31, 2021 | DORN, GERALD W. | reporter.nih.gov |
| The role of Huntingtin in endolysosomal trafficking and Huntington's disease pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $76,812 | September 18, 2024 | August 31, 2026 | FARMER, STEPHEN M | reporter.nih.gov |
| Modulation of Somatic Repeat Expansion as a Therapeutic Approach to Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $71,848 | April 1, 2023 | April 2, 2025 | BELGRAD, JILLIAN | reporter.nih.gov |
| Examining the Role of a Pathogenic HTT Isoform, HTT1a, in Somatic Expansion and RNA Aggregation in Huntington's Disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $68,124 | July 1, 2024 | June 30, 2027 | ALLEN, SARAH JANE | reporter.nih.gov |
| Interactions of intracellular calcium sensors with the pre-mRNA splicing factor Prp40 | NIH | National Institute of General Medical Sciences | 2021 | $43,665 | January 1, 2020 | July 31, 2021 | DIAZ-CASAS, ADALBERTO | reporter.nih.gov |
| Investigating the Role of Microglia in Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $42,917 | July 1, 2019 | July 1, 2021 | CRAPSER, JOSHUA DANIEL | reporter.nih.gov |
| Uncovering the Roles of Chaperonin CCT in Neural Health and Disease. | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $41,294 | February 7, 2023 | February 6, 2024 | LOTTES, ERIN | reporter.nih.gov |
| Functional impact of N6-Methyadenosine (m6A) modification in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $37,306 | May 1, 2022 | February 22, 2023 | NGUYEN, THAI BAO NGO | reporter.nih.gov |
| Determinants of cell type-specific vulnerability in Huntington's disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $35,313 | April 1, 2017 | June 30, 2021 | HEIMAN, MYRIAM | reporter.nih.gov |
| Investigating non-coding RNA 7SK in Huntington's Disease neurodegeneration using direct neuronal conversion | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $32,686 | June 1, 2022 | May 15, 2023 | CATES, KITRA L | reporter.nih.gov |
| Novel Insights into the Role of Prions in Polyglutamine Protein Homeostasis | NIH | National Institute of General Medical Sciences | 2024 | $28,337 | May 1, 2024 | November 8, 2024 | WILLIAMS, FELICIA NICOLE | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston, MA | 10 | $22.2 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 10 | $16.5 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 1 | $13.7 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 3 | $11.7 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 13 | $11.2 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 6 | $9.1 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 5 | $7.9 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 3 | $5.9 million | 0 | $0 |
| University of Florida | Gainesville, FL | 4 | $5.9 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 4 | $5.6 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 3 | $4.1 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 4 | $4.1 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 3 | $3.6 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 3 | $3.4 million | 0 | $0 |
| Buck Institute for Research on Aging | Novato, CA | 2 | $3.4 million | 0 | $0 |
| University of Calif-Lawrenc Berkeley Lab | Berkeley, CA | 2 | $3.2 million | 0 | $0 |
| Rockefeller University | New York, NY | 1 | $3.1 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 2 | $3 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 3 | $2.9 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 4 | $2.8 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 3 | $2.8 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 3 | $2.7 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 2 | $2.5 million | 0 | $0 |
| Washington University | Saint Louis, MO | 4 | $2.3 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 1 | $2.3 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 2 | $2.2 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 2 | $2.2 million | 0 | $0 |
| Mitochondria in Motion, Inc. | Saint Louis, MO | 2 | $2 million | 0 | $0 |
| J. David Gladstone Institutes | San Francisco, CA | 1 | $1.9 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 1 | $1.9 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 1 | $1.8 million | 0 | $0 |
| Duke University | Durham, NC | 3 | $1.8 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 2 | $1.7 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 1 | $1.7 million | 0 | $0 |
| The University of Central Florida Board of Trustees | Orlando, FL | 1 | $1.7 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 1 | $1.7 million | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 1 | $1.6 million | 0 | $0 |
| Tufts University | Medford, MA | 1 | $1.6 million | 0 | $0 |
| Emory University | Atlanta, GA | 3 | $1.6 million | 0 | $0 |
| T3D Therapeutics, Inc. | Research Triangle Park, NC | 1 | $1.6 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 1 | $1.6 million | 0 | $0 |
| University of California at Davis | Davis, CA | 1 | $1.5 million | 0 | $0 |
| University of Houston | Houston, TX | 1 | $1.5 million | 0 | $0 |
| University of Puerto Rico Med Sciences | San Juan, PR | 1 | $1.4 million | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 1 | $1.3 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 2 | $1.3 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 1 | $1.2 million | 0 | $0 |
| Origami Therapeutics, Inc. | San Diego, CA | 2 | $1.1 million | 0 | $0 |
| Biosensics, LLC | Newton, MA | 1 | $1.1 million | 0 | $0 |
| California Institute of Technology | Pasadena, CA | 1 | $1 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 2 | $1 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 1 | $826,279 | 0 | $0 |
| Columbia University | New York, NY | 1 | $777,642 | 0 | $0 |
| Corticometrics, LLC | Rockport, MA | 1 | $734,079 | 0 | $0 |
| Janusq, LLC | Rocky River, OH | 2 | $731,439 | 0 | $0 |
| Ayana Bio LLC | Boston, MA | 1 | $604,784 | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 1 | $561,046 | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 1 | $551,250 | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 1 | $535,142 | 0 | $0 |
| Neurano Bioscience | La Jolla, CA | 1 | $518,505 | 0 | $0 |
| Central Michigan University | Mount Pleasant, MI | 1 | $402,805 | 0 | $0 |
| Nuago Therapeutics INC | Chicago, IL | 1 | $400,000 | 0 | $0 |
| CUNY York College | Jamaica, NY | 1 | $371,521 | 0 | $0 |
| Texas Tech University Health Scis Center | Lubbock, TX | 1 | $318,653 | 0 | $0 |
| Huntington Medical Research Institutes | Pasadena, CA | 1 | $283,310 | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 1 | $195,000 | 0 | $0 |
| University of South Florida | Tampa, FL | 1 | $141,650 | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 1 | $116,947 | 0 | $0 |
| University of the Sciences Philadelphia | Philadelphia, PA | 1 | $93,024 | 0 | $0 |
| Georgia State University | Atlanta, GA | 1 | $41,294 | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 1 | $35,313 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 66 | $35,453,252 | 0 | $0 |
| 2024 | 79 | $41,949,593 | 0 | $0 |
| 2023 | 83 | $43,423,205 | 0 | $0 |
| 2022 | 86 | $43,318,198 | 0 | $0 |
| 2021 | 78 | $41,311,734 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.